NexoBrid (anacaulase or anacaulase-bcdb) is a topical medication FDA-approved to get rid of damaged skin from second- and third-degree burns wounds in adults. It contains a mixture of enzymes (proteins) from pineapple plants that help to remove dead skin tissue. NexoBrid (anacaulase) is applied onto the burn wound by a healthcare professional (HCP), left on for 4 hours, then removed along with the dead skin tissue. If needed, another NexoBrid (anacaulase) treatment can be given 24 hours after the first. Common side effects of this medication are itching and fever.
Removal of dead skin tissue from second- and third-degree burns
NexoBrid (anacaulase) contains a mixture of enzymes (proteins) from the pineapple plant. It breaks down dead skin tissue caused by a burn. The removal of dead skin tissue allows for new, healthy skin to grow in its place to help wounds heal.
Source: DailyMed
Wells well removing dead skin tissue removed after application
Lowers the rate of surgery and blood loss after a burn wound
Able to remove dead skin tissue within 4 hours
Application can lead to serious injury to surrounding skin
Not for chemical burns, or burns near medical devices (e.g., pacemakers, implants) and important body organs
Contains bromelain (a protein in pineapples), so not a safe option if you have an allergy to any pineapples or papayas
You'll typically receive NexoBrid (anacaulase) at a wound clinic or a hospital. This medication needs to be given by a HCP with the right tools and techniques to lower the risk of side effects.
NexoBrid (anacaulase) is available as a topical powder. It needs to be mixed with a gel before application. Your HCP will make sure that you receive this medication within 15 minutes after mixing.
Once NexoBrid (anacaulase) is applied to your burn wound, your care team will leave it on for 4 hours. Before your treatment, ask your care team what are some appropriate activities you can bring to help you pass the time.
Treatment with NexoBrid (anacaulase) can be painful. Typically, your care team will give you medication to help ease pain and discomfort at least 15 minutes before the application. Let your care team know if you experience pain during treatment.
Your care team will also give you a topical ointment, like Vaseline, to protect the skin outside of the treatment area and a topical antibiotic to prevent infection from the procedure.
You might need a second application of NexoBrid (anacaulase) 24 hours after the first application. Make sure to plan for some extra time for your procedure for the HCP to check how your wound is doing.
NexoBrid (anacaulase) can cause some serious health issues. This risk may be even higher for certain groups. If this worries you, talk to your doctor or pharmacist about other options.
Tell your healthcare team before treatment with NexoBrid (anacaulase) if you've been told you have an allergy to pineapples, bromelain (a type of protein in pineapple), papayas, or papain (a type of protein in papaya). Many of the enzymes found in NexoBrid (anacaulase) are from pineapples (which can cross-react with papayas). Watch out for signs and symptoms of allergic reactions, such as swelling, rash, itchy skin, or trouble breathing. Get medical attention right away if you have these signs and symptoms.
Treatment with NexoBrid (anacaulase) can cause serious pain. At least 15 minutes before application, your care team will provide pain management to help ease and control the pain. Let your care team know as soon as possible if you experience pain during application.
Risk factors: Applying this medication in areas with medical devices | Applying this medication near important body organs
NexoBrid (anacaulase) shouldn't be used in areas with medical devices, such as implants or pacemakers. It should also not be used near important body organs. Treatment with NexoBrid (anacaulase) can potentially expose them underneath the skin, which can be life-threatening. In order to prevent serious skin injury, your care team will protect the skin around the application area with an ointment similar to Vaseline.
Risk factor: History of blood problems
NexoBrid (anacaulase) might raise the risk of bleeding in people with blood problems or taking blood thinners (e.g., Eliquis (apixaban), warfarin (Coumadin)). Get medical attention right away if you have any signs of bleeding: black, red, or tarry stools; vomiting blood; unexplained bruises; bruises that get bigger; or bleeding that won’t stop.
NexoBrid contains 8.8% anacaulase. It's only available as a topical medication that's given by a HCP. Your HCP will determine how much NexoBrid (anacaulase) you need based on your body surface area (BSA), which takes into account your weight and height.
NexoBrid (anacaulase) can only be used to treat areas up to 20% BSA between 2 applications.
Adults: After cleaning and prepping the affected area, your care team will apply a layer of NexoBrid (anacaulase) 3 mm thick to cover the burn area. They'll cover the treated area with a dressing, then leave the medication on for 4 hours. After that, your care team will carefully scrape off the dead skin from the application area. If not all of the dead skin can be removed, you have multiple wounds, or the affected area(s) is more than 15% BSA, they might give you a second treatment 24 hours later.
Removal of dead skin tissue from second- and third-degree burns
Removal of damaged or burned skin
Prevention and treatment of infections caused by second- and third-degree burns
By signing up, I agree to GoodRx's Terms and Privacy Policy, and to receive marketing messages from GoodRx.
American Academy of Allergy, Asthma and Immunology. (n.d.). Cross-reactivity defined.
Manna, B., et al. (2023). Wound Debridement. StatPearls.
National Center for Complementary and Integrative Health. (2020). Bromelain.
Shoham, Y., et al. (2023). Bromelain‐based enzymatic burn debridement: A systematic review of clinical studies on patient safety, efficacy and long‐term outcomes. International Wound Journal.
Shoham, Y., et al. (2023). Early Enzymatic Burn Debridement: Results of the DETECT Multicenter Randomized Controlled Trial. Journal of Burn Care & Research.
U.S. Food & Drug Administration. (2024). Drug Trials Snapshot: NEXOBRID.
Vericel Corporation. (2022). Vericel announces FDA approval of NexoBrid for the treatment of severe thermal burns in adults. Globe Newswire.
Vericel Corporation. (2023). Nexobrid- anacaulase-bcdb kit [package insert]. DailyMed.
Research prescriptions and over-the-counter medications from A to Z, compare drug prices, and start saving.